Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma.


Uterine sarcomas are a heterogeneous group of neoplasms with a propensity for metastasis and resistance to conventional therapy and represent 8% of all uterine malignancies. They consist of pure stromal tumors, the endometrial stromal sarcomas (ESSs) and leiomyosarcomas, mixed epithelial and mesenchymal tumors and carcinosarcomas [1]. The poor prognosis of… (More)
DOI: 10.1093/annonc/mdp431